Neurizon Therapeutics receives FDA approval for NUZ-001 ALS drug candidate trial.

Neurizon Therapeutics has announced that the US FDA has cleared the use of its drug candidate, NUZ-001, in a clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company is focused on developing treatments for neurodegenerative diseases and NUZ-001 is its lead drug candidate for ALS, a devastating neurodegenerative condition that affects nerve cells controlling voluntary muscles.